Why medtech firms are putting diabetes tech in consumer devices

As Abbott develops a line of wearable wellness devices, and Dexcom makes a CGM for people with diabetes who don’t take insulin, both companies are turning to new users for future growth.

By Elise Reuter • Updated Aug. 31, 2023

Medtronic raises earnings forecast amid supply chain, diabetes business improvements

The company also shared an update on the planned divestment of its monitoring and respiratory interventions segments.

By Elise Reuter • Aug. 22, 2023

Tandem’s chief commercial officer to resign ahead of insulin pump rollout

Brian Hansen is stepping down as Tandem prepares to roll out its new Mobi pump.

By Elise Reuter • Aug. 21, 2023

Dexcom, Abbott ramp up DTC marketing amid fight for share of growing diabetes market

As insurers cover continuous glucose monitors for more people, device-makers are taking a page from the pharma marketing playbook.

By Elise Reuter • Aug. 17, 2023

Insulet claims EOFlow copied patch-pump design in patent suit

Insulet filed the lawsuit as competitor Medtronic plans to buy EOFlow for $738 million.

By Elise Reuter • Aug. 15, 2023

Senseonics seeks iCGM designation for implantable glucose monitor

The company also plans to submit results of a pivotal trial for a version of its device that can be worn for a year.

By Elise Reuter • Aug. 11, 2023

Device volumes to hold up against threat of Wegovy, other GLP-1 drugs: analysts

Issues such as “nontrivial side effects, cost concerns and patient persistence” will mean physicians continue to use medical devices, analysts say.

By Nick Paul Taylor • Aug. 9, 2023

Dexcom hails CGM share gains as driver of 25% revenue growth in Q2

International market share gains and expanding coverage in the U.S. led the CGM maker to raise its revenue forecast for 2023.

By Nick Paul Taylor • July 28, 2023

Sanofi’s Felix Lee talks DarioHealth partnership, future of digital health

The pharmaceutical company struck a strategic agreement with digital health company DarioHealth last year aimed at helping patients with diabetes manage their blood sugar levels. 

By Elise Reuter • July 21, 2023

Abbott Q2 net profit falls as weaker COVID test sales drag on revenue

Stronger medical device sales and a recovery in the infant formula business partly offset the impact of reduced COVID-19 testing.

By Susan Kelly • July 20, 2023

Tandem’s Mobi insulin pump could reaccelerate growth next year: analyst

The device, which is smaller than Tandem’s past pumps, could drive more people to switch from insulin injections, an analyst with Craig-Hallum said.

By Elise Reuter • July 12, 2023

Medtronic secures Medicare coverage for MiniMed 780G insulin pump

Medtronic has begun processing orders and will start shipping devices over the next few weeks.

By Nick Paul Taylor • July 10, 2023

BD to shed 60 jobs as COVID demand, diabetes spinoff affect manufacturing plant

The cuts are the latest in a wave of workforce reductions by medtech companies including Abbott Laboratories, Cook Medical, Illumina and Thermo Fisher Scientific.

By Nick Paul Taylor • July 7, 2023

Q&A: Dexcom’s Lawver shares strategy behind CGM for non-insulin users

The continuous glucose monitor in development for people with Type 2 diabetes who don’t take insulin could expand the CGM market to 25 million more people in the U.S., the company’s new chief commercial officer said.

By Elise Reuter • June 30, 2023

Diabetes remains fastest-growing medtech market despite some risk from new drugs: analysts

The medicines could apply “short-lived pressures” to medtech companies by affecting the use of insulin, Mizuho analysts say. 

By Nick Paul Taylor • June 30, 2023

More than 1 billion people could have diabetes by 2050, study says

A pair of studies published in the Lancet show that spending on diabetes care is expected to rise, but more work is needed to address structural inequities that affect access to treatment.

By Elise Reuter • June 26, 2023

Medtronic links 780G insulin pump to benefits in kids as it works to grow sales

A clinical trial found adolescent users of the pump can achieve improved blood glucose control without precisely counting carbohydrates.

By Nick Paul Taylor • June 26, 2023

Dexcom targets 25M Americans with new CGM aimed at non-insulin-using diabetics

The device will last for 15 days, include a cash-pay option and come with software designed for the needs of people who are yet to require insulin.

By Nick Paul Taylor • June 26, 2023

Bigfoot links smart insulin pen cap to improved glycemic control in real-world study

Using the system can bring “rapid and durable improvement” in glycemic control for older adults with Type 2 diabetes who use multiple daily injections, researchers found.

By Nick Paul Taylor • June 22, 2023

Novo Nordisk says in talks to acquire French device-maker Biocorp for $165M

The offer per share is about 20% more than Biocorp’s closing stock price on June 2. The two companies plan to focus on drug delivery solutions for chronic diseases, such as diabetes.

By Elise Reuter • Updated June 6, 2023

Medtronic posts profit, sales growth in Q4, agrees to buy Korean diabetes patch maker

The company is “confident in delivering durable revenue growth in the year ahead” amid continued improvements in procedure volumes.

By Peter Green • May 25, 2023

Medtronic agrees to buy Korean insulin patch pump maker for $738m to boost diabetes business

The tubeless, disposable insulin patch made by EOFlow will be integrated into Medtronic’s MiniMed 780G system.

By Elise Reuter • May 25, 2023

Beta Bionics wins FDA nod to challenge Medtronic for automated insulin pump market

Beta Bionics’ device, aimed at people with Type 1 diabetes, has eliminated most of the data entry required by competitors.

By Nick Paul Taylor • May 22, 2023

Diabetes app developers must generate more data on clinical effectiveness, study says

The researchers saw a need for more data on the wider clinical effectiveness of apps in the management of Type 1 diabetes and prediabetes.

By Nick Paul Taylor • May 16, 2023

Embecta joins Tidepool to develop insulin pump, raises Q2 growth outlook

Embecta advanced its pump project by partnering with Tidepool, a nonprofit that has developed diabetes management software that can work across different brands of pumps and monitors.

By Nick Paul Taylor • May 15, 2023